New Developments in Pharma Companies: $AZN $GSK $LLY

We have previously voiced concerns over the future of AstraZeneca (NYSE: AZN), in particular its lackluster pipeline (read more on high dividend pharma stocks). Based on the company’s situation, we anticipated that it would engage in M&A activity to bolster its pipeline. Yesterday’s announcement of AZN’s $1.3 billion acquisition of Ardea Biosciences falls in line with our speculation. The acquisition adds Phase III gout drug, lesinurad. Gout is prevalent in both developing and developed markets, but lesinurad is not expected to be a blockbuster drug given the cheapness and effectiveness of allopurinol. Peak sales estimates for the drug are less than a billion. We think this is just the beginning of AZN’s acquisition spree. It would make sense for AZN to build out its cardio, respiratory, and central nervous system portfolios since it already has existing products in those areas, but we would like to see the company make a concerted effort at enhancing its oncology franchise. So in short, Ardea will not be enough to save AZN, but additional tuck-in acquisitions to compensate for the upcoming Seroquel, Nexium, and Crestor expiries. This is a critical year for the company. If it does not succeed in building out its pipeline, the company will need to reevaluate its model and cost structure.

GlaxoSmithKline plc (ADR) (NYSE:GSK)

AZN is not the only big pharma with acquisition news, last week GlaxoSmithKline (NYSE: GSK), held by Warren Buffet, Christopher James, and Ken Fisher, made a $2.6 billion offer for Human Genome Sciences (NASDAQ: HGSI). GSK is already HGSI’s main partner and CEO Andrew Witty has reiterated what he sees as a logical fit saying, “We[GSK] absolutely believe that we are the compelling owner for this business…we have the rights and the operational control for the three main assets…” If the deal goes through, GSK would fully own Benlysta (lupus), which missed expected sales by a couple million this past quarter, darapladib (cardiovascular), and albiglutide (diabetes). Investors have been wondering if a “white knight” will come in, topping GSK’s bid; we do not think that is a likely scenario given the depth and breadth of the two companies’ partnership. The more likely outcome is that GSK may up its $13/share bid but not by much. Like AZN, GSK is also trying to recover from its patent cliff and dropping Avandia sales, but its pipeline is far more promising than AZN’s on the back of positive data for dabrafenib (BRAF inhibitor for melanoma) and lung cancer vaccine this past quarter. Q1 was a disappointing one, with revenue increasing a paltry 1% q-o-q, but we are optimistic on GSK’s prospects this year.

Competitor Eli Lilly (NYSE: LLY) also reported some news with a strong Q1 with EPS of $0.92 versus consensus estimates of $0.78. Robust Cymbalta sales, better-than-expected sales of Zyprexa (LLY’s antipsychotic drug), and resulting higher gross margins (78.6%) drove the earnings beat. Zyprexa generated $563 million in revenue while the street expected $488 million. Animal Health did very well with sales of $491 million and Straterra and Forteo revenues came in on the high side. Thus, management raised 2012 guidance from $3.10 to $3.20 in EPS to $3.15 to $3.30 on increased revenue contribution from Zyprexa. In terms of pipeline updates, solanezumab for Alzheimer’s will release data this summer and JAK 1/2 for rheumatoid arthritis has potential to begin Phase III trials this year based on data from the Phase IIb study should be released at the European League Against Rheumatism (EULAR) in June. Tasisulam, survivin ASO, and SARM/Cialis have been dropped from development. We are not concerned about the discontinuation of development for these products as they were not a huge focus or upcoming catalyst for the company.

Biotech Insider Alert - $6 Stock To Hit $40

$200 Million Dollar Healthcare Hedge Fund's #1 Best Idea Right Now

The best healthcare hedge fund out there right now is one of the largest shareholders in this biotech stock. The fund returned more than 20% in each of the last 2 years with a virtually fully hedged portfolio, and it's sending out a BUY signal on this biotech stock. Get your FREE REPORT today (retail value of $300)

This is a FREE report from Insider Monkey. Credit Card is NOT required.
Comments
Insider Monkey Small Cap Strategy
Insider Monkey Small Cap Strategy

Insider Monkey beat the market by 52 percentage points in 24 months. Our beta is only 1.2 (don't click this link if beating the market isn't important to you).

Lists

The Oldest Money Managers

The Greatest Directors in the World

Largest Animals in the World

World’s Most Expensive Desserts

Best Selling Comic Books of All Time

A-list Actors who Sabotaged Their Career

Rappers With a College Degree

The Best Jazz Albums of all Time

The Most Influential Jazz Musicians

The World’s Most Famous Photographers

The Best Oscar-Winning Songs

Most Influential Choreographers Ever

Most Expensive Department Stores in the World

The Most Expensive Stolen Paintings in the World

The World’s Most Expensive Teas

Top Oscar Record Holders

The Most Expensive Flowers in the World

Countries With a Booming Film Industry

Most Expensive Cupcakes in the World

Uncommon European Escapes

The Most Stolen Artists in History

Best Travel Destinations in Australia

World’s Most Expensive Musical Instruments

World’s Most Famous Animals

Most Expensive Cakes in the World

Most Expensive Kosher Champagne in the World

Most Expensive Kosher Wine in the World

The Most Surprisingly Dark Fairy Tales

Most Popular Travel Destinations in Asia

The 10 Most Expensive Dresses Ever Worn to the Oscars

World’s Most Visited Art Museums

Best Countries for Photographers to Work in

Best Paid Jobs in the Film Industry

The Most Renowned Recovered Paintings Ever

Child Stars That Turned out Just Fine

Books That Were Banned in the Past Century

World’s Richest Dancers

Best Remedies against Bad Breath

Foods That Improve Your Skin Texture

Best-Selling Children’s Books of all Time

Foods That Boost Your Libido

Best-Selling Books of all Time

The Most Expensive Academy Awards Jewelry in History

Most Expensive Japanese Restaurant In New York City

The Best B-Boy Movies

Most Awesome Hip Hop Documentaries

Foods That Stain Your Teeth

Richest Doctors in the World

The Best Movie Sountracks Ever

The Highest Grossing Musicals on Broadway

Subscribe

Enter your email:

Delivered by FeedBurner

X

Thanks! An email with instructions is sent to !

Your email already exists in our database. Click here to go to your subscriptions

Insider Monkey returned 129% in 2.5 years!! Wondering How?

Download a complete edition of our newsletter for free!